Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).
Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286
Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.
Beck J. et alDigital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 ;59:1732-41
Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA.
High-quality genomic analysis is critical for personalized pharmacotherapy in patients with cancer
Chronix Biomedical is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the ASCO Annual Meeting.
The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI) score as a prognostic test in head and neck cancer.
First study of a liquid biopsy to predict response to immunotherapy...
Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...
The best way to fight cancer is to diagnose it in its early stage...
World Cancer Day is a perfect opportunity to focus on your health state...
Julia Beck, Margret Rave-Fraenk, et al. Prognostic value of cell-free DNA in patients with oropharyngeal cancers.J Clin Oncol 34, 2016 (suppl; abstr e17511).
Tumor derived plasma cell-free DNA (TcfDNA) is described as biomarker to monitor tumor burden in cancer. Large somatic genome aberrations are hallmarks of malignancies and detectable in cfDNA. However, levels of TcfDNA are variable according to cancer types. We obtained copy-number instability (CNI) scores of cfDNA in treatment-naïve head and neck cancers before and after therapy.